Skip to main content

Mentari Therapeutics, Inc.

corporate_fare Company Profile

Mentari Therapeutics, Inc.

MTRI·NASDAQ·Life Sciences·CIK 0001728328

Mentari Therapeutics, Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system found throughout the human body and responsible for many homeostatic functions; CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. The company's research efforts target the treatment of diseases with high unmet medical needs. On March 4, 2026, the InMed Board ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment, which constituted the only revenue-generating commercial operations of InMed. As of June 30, 2026, BayMedica had wound down all of its operating activities, and had two remaining employees who departed on July 31, 2026, as well as a commercial lease which will terminate at the end of August. Following the wind down of commercial operations, InMed's remaining activities have consisted of preclinical development of its Product Candidates, including INM-901 for Alzheimer's disease, INM-089 for dry Age-related Macular Degeneration or dry AMD, and INM-755 (cannabinol) cream. InMed does not currently intend to devote significant resources to advancing these Product Candidates, and any further development of them would require InMed to obtain additional financing, of which there can be no assurance. The company has sought to focus on the research and development of preferential signaling ligands of CB1 and CB2, and has produced a library of novel, proprietary drug candidates, or Product Candidates. These Product Candidates are patentable new chemical entities, or NCEs, for pharmaceutical development, aimed at targeting diverse clinical indications. The current potential pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer's disease, dry AMD, and Epidermolysis Bullosa, or EB.

Mentari Therapeutics, Inc. (NASDAQ:MTRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for MTRI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for MTRI spans 8-K.

Recent high-impact activity:

  • Mentari Replaces Both Legacy Auditors with Deloitte Days After Merger Close
  • Mentari Posts First Post-Merger Financials: $63.0M Nine-Month Loss, $45.8M Cash, $490M Raised

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$12.56M
Diluted EPS
-$3.12
Op. Cash Flow
-$8.64M
Cash & Equivalents
$2.19M
Debt / Equity
0.00×
Shares Outstanding
5.34M sh
Source: 10-K · filed 2026-09-09 · accession 0001213900-26-098419

Short Interest & Short Volume

On November 19, 2026, 35.2% of MTRI volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)35.2% of 6,010 shares on November 19, 2026
5-day average short volume4.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$14.21 -6.82% today
52-week range · as of 2026-11-19 $12.2 – $233
Market cap
$750.22M
Volume
55.3K (1.9× avg)
3-mo avg 29.2K
Live data · 2026-11-20 20:53 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MTRI - Latest Insights

MTRI
Nov 19, 2026, 5:37 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.25
Real-time Price: $14.21 info
Change: -$1.04 (-7%) info
Market Cap: $750.222M info
MTRI
Nov 16, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.00
Real-time Price: $14.21 info
Change: -$4.80 (-25%) info
Market Cap: $750.222M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets